Patent: 9,650,433
✉ Email this page to a colleague
Summary for Patent: 9,650,433
Title: | Modified glycoproteins |
Abstract: | Sulfated glycoproteins, and methods of making and using such sulfated glycoproteins, are described. |
Inventor(s): | Bulik; Dorota A. (Malden, MA), Bosques; Carlos J. (Arlington, MA), Collins; Brian Edward (Arlington, MA), Hains; Maurice Gaston (Brockton, MA), Washburn; Nathaniel J. (Littleton, MA), Meador; James (Framingham, MA), Smith; Sean (Littleton, MA), Bhatnagar; Naveen (Framingham, MA) |
Assignee: | Momenta Pharmaceuticals, Inc. (Cambridge, MA) |
Application Number: | 14/118,269 |
Patent Claims: | see list of patent claims |
Details for Patent 9,650,433
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REOPRO | abciximab | Injection | 103575 | 12/22/1994 | ⤷ Try a Trial | 2031-05-20 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2031-05-20 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2031-05-20 |
Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 12/10/1997 | ⤷ Try a Trial | 2031-05-20 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 05/12/1998 | ⤷ Try a Trial | 2031-05-20 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |